Optomed Oyj Valuation
Is OPTOMED undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OPTOMED when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OPTOMED (€3.96) is trading below our estimate of fair value (€27.08)
Significantly Below Fair Value: OPTOMED is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OPTOMED?
Key metric: As OPTOMED is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is OPTOMED's PS Ratio? | |
|---|---|
| PS Ratio | 5.7x |
| Sales | €13.60m |
| Market Cap | €77.70m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.2x |
| Enterprise Value/EBITDA | -14.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does OPTOMED's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.8x | ||
NXTMH Nexstim | 3.7x | 15.7% | €34.9m |
MODU Modulight Oyj | 6x | 36.9% | €39.2m |
BIOBV Biohit Oyj | 2.5x | 13.5% | €34.9m |
REG1V Revenio Group Oyj | 7x | 12.2% | €718.1m |
OPTOMED Optomed Oyj | 5.7x | 29.8% | €77.5m |
Price-To-Sales vs Peers: OPTOMED is expensive based on its Price-To-Sales Ratio (5.7x) compared to the peer average (4.8x).
Price to Sales Ratio vs Industry
How does OPTOMED's PS Ratio compare vs other companies in the European Medical Equipment Industry?
| 33 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 33 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: OPTOMED is expensive based on its Price-To-Sales Ratio (5.7x) compared to the European Medical Equipment industry average (3.7x).
Price to Sales Ratio vs Fair Ratio
What is OPTOMED's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.7x |
| Fair PS Ratio | 5.2x |
Price-To-Sales vs Fair Ratio: OPTOMED is expensive based on its Price-To-Sales Ratio (5.7x) compared to the estimated Fair Price-To-Sales Ratio (5.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €3.96 | €5.83 +47.5% | 14.6% | €7.00 | €5.00 | n/a | 3 |
| Nov ’25 | €3.81 | €6.37 +67.3% | 13.2% | €7.50 | €5.50 | n/a | 3 |
| Oct ’25 | €4.66 | €6.37 +36.6% | 13.2% | €7.50 | €5.50 | n/a | 3 |
| Sep ’25 | €5.32 | €6.43 +20.9% | 12.0% | €7.50 | €5.70 | n/a | 3 |
| Aug ’25 | €6.19 | €6.20 +0.2% | 6.5% | €6.60 | €5.80 | n/a | 2 |
| Jul ’25 | €6.05 | €6.20 +2.5% | 6.5% | €6.60 | €5.80 | n/a | 2 |
| Jun ’25 | €7.27 | €6.63 -8.8% | 14.7% | €8.00 | €5.80 | n/a | 3 |
| May ’25 | €5.00 | €5.80 +16.0% | 33.3% | €8.00 | €3.30 | n/a | 3 |
| Apr ’25 | €3.95 | €5.80 +46.8% | 33.3% | €8.00 | €3.30 | n/a | 3 |
| Mar ’25 | €3.60 | €5.80 +61.3% | 33.3% | €8.00 | €3.30 | n/a | 3 |
| Feb ’25 | €3.82 | €5.80 +52.0% | 33.3% | €8.00 | €3.30 | n/a | 3 |
| Jan ’25 | €3.72 | €5.80 +56.1% | 33.3% | €8.00 | €3.30 | n/a | 3 |
| Dec ’24 | €3.03 | €5.80 +91.4% | 33.3% | €8.00 | €3.30 | n/a | 3 |
| Nov ’24 | €2.56 | €5.80 +126.6% | 33.3% | €8.00 | €3.30 | €3.81 | 3 |
| Oct ’24 | €2.72 | €5.80 +113.6% | 33.3% | €8.00 | €3.30 | €4.66 | 3 |
| Sep ’24 | €3.11 | €6.03 +94.0% | 27.1% | €8.00 | €4.00 | €5.32 | 3 |
| Aug ’24 | €3.47 | €6.37 +83.7% | 20.5% | €8.00 | €4.80 | €6.19 | 3 |
| Jul ’24 | €3.14 | €6.37 +102.8% | 20.5% | €8.00 | €4.80 | €6.05 | 3 |
| Jun ’24 | €3.15 | €6.37 +102.4% | 20.5% | €8.00 | €4.80 | €7.27 | 3 |
| May ’24 | €4.05 | €6.37 +57.4% | 20.5% | €8.00 | €4.80 | €5.00 | 3 |
| Apr ’24 | €3.93 | €6.37 +62.0% | 20.5% | €8.00 | €4.80 | €3.95 | 3 |
| Mar ’24 | €3.85 | €6.37 +65.4% | 20.5% | €8.00 | €4.80 | €3.60 | 3 |
| Feb ’24 | €4.50 | €6.70 +49.1% | 25.9% | €9.00 | €4.80 | €3.82 | 3 |
| Jan ’24 | €3.75 | €6.43 +71.8% | 31.8% | €9.00 | €4.00 | €3.72 | 3 |
| Dec ’23 | €3.27 | €6.43 +97.0% | 31.8% | €9.00 | €4.00 | €3.03 | 3 |
| Nov ’23 | €2.52 | €7.23 +187.0% | 27.1% | €9.00 | €4.50 | €2.56 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Revenio Group Oyj
€738.8m
Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally.
REG1V
€27.00
7D
-7.7%
1Y
10.3%
Biohit Oyj
€34.9m
A biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide.
BIOBV
€2.30
7D
-6.5%
1Y
17.9%